VOGX Stock Forecast: Vogenx, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 15 Aug 2026 — in the weakest quartile.
VOGX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Vogenx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (68): Smaller than most of the companies we track.
Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
VOGX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VOGX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VOGX appears on the weeks it earns a place.
VOGX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Vogenx, Inc. (VOGX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- −52.5×
Cheaper than 94% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- 157.3%
- Return on assets
- −212.2%
- Dividend yield
- —
Higher than 98% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
VOGX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vogenx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about VOGX stock
How does Ticker Nerd's model rank VOGX?
As at 15 Aug 2026, Vogenx, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (68 of 100).
What is the VOGX stock forecast for 2030?
No analyst covering Vogenx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VOGX are extrapolating price history, which says nothing about the business.
What does Vogenx, Inc. do?
Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders.
About Vogenx, Inc.
Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders. The company’s current work centers on diseases linked to human metabolism dysfunction, including post-bariatric hypoglycemia and gastroparesis. Its lead product candidate, mizagliflozin, is an orally administered small-molecule drug designed to modulate glucose absorption through SGLT1 inhibition. Vogenx also studies additional metabolic indications such as obesity and related postprandial disorders, reflecting a pipeline aimed at conditions with limited treatment options. Headquartered in Raleigh, North Carolina, Vogenx operates as a drug development business within the healthcare sector, where its role is to advance investigational therapies through clinical testing and toward potential regulatory review.
CEO Mr. James Green · 4 employees · United States · https://vogenx.com